PHOENIX, July 27, 2018 (GLOBE NEWSWIRE) — INSYS Therapeutics, Inc. (NASDAQ: INSY) announced that today it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the company’s New Drug Application…Original Article
INSYS Therapeutics Receives Complete Response Letter from FDA for Buprenorphine NDA
